THIRD QUARTER (JULY -
- Order intake
SEK 240.7 M (219.1) -
Net sales
SEK 252.9 M (210.9) -
Operating profit
SEK 28.6 M (12.0) -
Profit after tax
SEK 21.6 M (10.1) -
Earnings per share before/after dilution
SEK 0.63 (0.29) -
Cash flow
SEK 63.5 M (-48.0) -
Order backlog
SEK 1,966.3 M (1,715.2) at the end of the period
NINE MONTHS (JANUARY -
- Order intake
SEK 686.5 M (704.1) -
Net sales
SEK 722.5 M (579.3) -
Operating profit
SEK 70.5 M (22.0) -
Profit after tax
SEK 50.0 M (9.6) -
Earnings per share before/after dilution
SEK 1.46 (0.28) -
Cash flow
SEK 144.7 M (4.0)
SIGNIFICANT EVENTS DURING THE THIRD QUARTER
University Medical Center Groningen inthe Netherlands purchased Micro-RayStation for pre-clinical research.-
RayCare in clinical use with CyberKnife at
Lausanne University Hospital (CHUV) inSwitzerland . RaySearch and MedAustron expand their partnership through a new strategic research agreement.-
Henrik Bergentoft leaves the position as CFO.
Annika Blondeau Henriksson has been appointed interim CFO. RaySearch 's business partner IBA has placed an order for RayStation and RayCare for installation atCRO National Cancer Institute (C.R.O.) inAviano, Italy .- Baptist Health Lexington in the US has placed an order for RayStation to two of its major centers.
Oregon Health & Science University in the US has placed an order for RayStation.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
RaySearch has received an order fromIsrael -based P-Cure and is deepening its collaboration focusing on advanced proton therapy solutions.The Paul Scherrer Institute inSwitzerland has placed an order for RayStation.The Mass General Cancer Center in the US has placed an order and thereby plans to expand its use of RayStation to proton treatment planning.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, CEO +46 (0)8 510 530 00, johan.lof@raysearchlabs.com
The information contained in this interim report is such that
WEBCAST
CEO Johan Löf and interim CFO
Link to webcast:
You can also join the webcast by phone:
US: +1 (1) 631 570 56 13
About
* Subject to regulatory clearance in some markets.
https://news.cision.com/raysearch-laboratories/r/interim-report-january-1---september-30--2023,c3877750
https://mb.cision.com/Main/1102/3877750/2437036.pdf
(c) 2023 Cision. All rights reserved., source